The FDA has approved Kybella (sodium deoxycholate), from Kythera Biopharmaceuticals, also known as ATX-101, for improvement in the appearance of...
Nicorette Invisi Patch relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. Nicorette Invisi Patch is indicated in pregnant and lactating women making a quit attempt (see section 4.6). If possible, Nicorette Invisi Patch should be used in conjunction with a behavioural support programme.
Aripiprazole is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1). Aripiprazole is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).
Doctors should measure central obesity to assess cardiovascular risk – even in patients with normal BMI.
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses,...
Kythera Biopharmaceuticals, Inc. announced it has submitted a Marketing Authorization Application (MAA) in the European Union (EU), seeking approval for...